Gag Mutations Strongly Contribute to HIV-1 Resistance to Protease Inhibitors in Highly Drug-Experienced Patients besides Compensating for Fitness Loss-Reference-Cited by-同舟云学术

Gag Mutations Strongly Contribute to HIV-1 Resistance to Protease Inhibitors in Highly Drug-Experienced Patients besides Compensating for Fitness Loss

Published:2009-03-20 Issue:3 Volume:5 Page:e1000345
ISSN:1553-7374
Container-title:PLoS Pathogens
language:en
Short-container-title:PLoS Pathog

Author:

Dam Elisabeth,Quercia Romina,Glass Bärbel,Descamps Diane,Launay Odile,Duval Xavier,Kräusslich Hans-Georg,Hance Allan J.,Clavel François,

Publisher

Public Library of Science (PLoS)

Subject

Virology,Genetics,Molecular Biology,Immunology,Microbiology,Parasitology

Reference31 articles.

1. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.;JH Condra;Nature,1995

2. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir.;A Molla;Nat Med,1996

3. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.;F Mammano;J Virol,2000

4. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults.;JD Barbour;J Virol,2002

5. HIV drug resistance.;F Clavel;N Engl J Med,2004

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular mechanisms behind the generation of pro-oncogenic HIV-1 matrix protein p17 variants;Journal of General Virology;2024-04-30

2. HIV-1 envelope facilitates the development of protease inhibitor resistance through acquiring mutations associated with viral entry and immune escape;Frontiers in Microbiology;2024-04-18

3. Comparative Evaluation of Bioinformatic Pipelines for Full-Length Viral Genome Assembly;2024-03-14

4. A detailed characterization of drug resistance during darunavir/ritonavir monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance;Journal of Antimicrobial Chemotherapy;2023-12-28

5. A detailed characterisation of drug resistance during darunavir/ritonavir (DRV/r) monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance;2023-10-15